<DOC>
	<DOC>NCT00948168</DOC>
	<brief_summary>The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.</brief_summary>
	<brief_title>Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>type 2 diabetes subjects 40 to 80 years body mass index (BMI) between 25 and 40 kg/mÂ² baseline glycated haemoglobin (HbA1c) &gt; 7.0 %, despite a maximallytolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin previous or current use of glitazone previous use of systemic glucocorticoids, weightreducing drug(s) such as sibutramine previous exposure to GLP1 receptor agonist or DPP4 inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>T2DM</keyword>
	<keyword>exenatide</keyword>
	<keyword>HbA1c</keyword>
	<keyword>weight</keyword>
	<keyword>waist circumference</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>beta-cell function</keyword>
</DOC>